

CORRECTION

Open Access



Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

Alexandra Leary

Alexandra Leary¹, Purificación Estévez-García², Renaud Sabatier³, Isabelle Ray-Coquard⁴, Margarita Romeo⁵, Pilar Barretina-Ginesta⁶, Marta Gil-Martin⁷, Elena Garralda⁸, Joaquim Bosch-Barrera⁶, Teresa Morán⁵, Paloma Martin-Martorell⁹, Ernest Nadal⁷, Pere Gascón¹⁰, Jordi Rodon¹¹, Jose M Lizcano^{12,13}, Pau Muñoz-Guardiola^{12,14}, Gemma Fierro-Durán¹⁴, Oriol Pedrós-Gámez¹⁴, Héctor Pérez-Montoyo¹⁴, Marc Yeste-Velasco¹⁴, Marc Cortal¹⁴, Antonio Pérez-Campos¹⁴, Jose Alfon¹⁴, Carles Domenech^{14*}, Alejandro Pérez-Fidalgo^{9†} and Ana Oaknin^{8†}

BMC Cancer (2024) 24:876

<https://doi.org/10.1186/s12885-024-12501-5>

†Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.

The online version of the original article can be found at <https://doi.org/10.1186/s12885-024-12501-5>.

*Correspondence:

Carles Domenech
carles.domenech@abilitypharma.com

¹Medical Oncology, Institut Gustave Roussy, Villejuif, France

²Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain

³Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France

⁴Medical Oncology, Centre Léon Bérard, Lyon, France

⁵Department of Medical Oncology, Department of Medicine, Institut Català d'Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona, Badalona, Spain

⁶Medical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d'Oncologia (ICO), Medical School University of Girona (UdG), Girona, Spain

⁷Medical Oncology, Catalan Institute of Oncology and IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain

⁸Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

⁹Medical Oncology, INCLIVA-Hospital Clínico Universitario, Valencia, Spain

¹⁰Medical Oncology Service, Hospital Clínic. Universitat de Barcelona, Barcelona, Spain

¹¹Early Drug Development, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

¹²Department of Biochemistry and Molecular Biology, Institut de Neurociències, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain

¹³Protein Kinases in Cancer Research, Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain

¹⁴Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is:

Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.

Published online: 29 July 2024

Reference

1. Leary A, Estévez-García P, Sabatier R et al. ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer. *BMC Cancer*. 2024;24:876. <https://doi.org/10.1186/s12885-024-12501-5>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.